Core Viewpoint - Tianyi Medical has received EU MDR certification for multiple products, indicating compliance with the latest EU medical device regulations, which enhances its market access and sales potential in Europe [1][3]. Trading Information Summary - On November 5, 2025, Tianyi Medical's stock closed at 58.8 yuan, up by 5.0%, with a turnover rate of 12.94% and a trading volume of 37,500 shares, resulting in a transaction value of 216 million yuan [1]. - The net inflow of main funds was 18.84 million yuan, while speculative funds saw a net inflow of 13.12 million yuan; however, retail investors experienced a net outflow of 31.97 million yuan [1][3]. Company Announcement Summary - Tianyi Medical has obtained EU MDR certification for products including Extracorporeal Blood Tubing Set, Oral/Enteral Syringe, Oral/Enteral Syringe with ENFit connector, and Arterial-Venous Fistula Needle Set, with the latter being a newly certified product [1][3]. - The certification, effective from November 4, 2025, and valid until January 5, 2028, signifies that the company's products meet the latest EU regulatory requirements, facilitating their promotion and sales in overseas markets [1].
股市必读：天益医疗（301097）11月5日主力资金净流入1884.38万元